BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22163192)

  • 1. Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIα activity through ATP-competitive inhibition.
    Ponder J; Yoo BH; Abraham AD; Li Q; Ashley AK; Amerin CL; Zhou Q; Reid BG; Reigan P; Hromas R; Nickoloff JA; LaBarbera DV
    Mar Drugs; 2011; 9(11):2397-2408. PubMed ID: 22163192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SET and transposase domain protein Metnase enhances chromosome decatenation: regulation by automethylation.
    Williamson EA; Rasila KK; Corwin LK; Wray J; Beck BD; Severns V; Mobarak C; Lee SH; Nickoloff JA; Hromas R
    Nucleic Acids Res; 2008 Oct; 36(18):5822-31. PubMed ID: 18790802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
    Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
    PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metnase mediates chromosome decatenation in acute leukemia cells.
    Wray J; Williamson EA; Sheema S; Lee SH; Libby E; Willman CL; Nickoloff JA; Hromas R
    Blood; 2009 Aug; 114(9):1852-8. PubMed ID: 19458360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metnase promotes restart and repair of stalled and collapsed replication forks.
    De Haro LP; Wray J; Williamson EA; Durant ST; Corwin L; Gentry AC; Osheroff N; Lee SH; Hromas R; Nickoloff JA
    Nucleic Acids Res; 2010 Sep; 38(17):5681-91. PubMed ID: 20457750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIα and potent anticancer agent.
    Li L; Abraham AD; Zhou Q; Ali H; O'Brien JV; Hamill BD; Arcaroli JJ; Messersmith WA; LaBarbera DV
    Mar Drugs; 2014 Sep; 12(9):4833-50. PubMed ID: 25244109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
    Gardner L; Malik R; Shimizu Y; Mullins N; ElShamy WM
    Breast Cancer Res; 2011 May; 13(3):R53. PubMed ID: 21595939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine.
    Marshall KM; Matsumoto SS; Holden JA; Concepción GP; Tasdemir D; Ireland CM; Barrows LR
    Biochem Pharmacol; 2003 Aug; 66(3):447-58. PubMed ID: 12907244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.
    Zhou Q; Abraham AD; Li L; Babalmorad A; Bagby S; Arcaroli JJ; Hansen RJ; Valeriote FA; Gustafson DL; Schaack J; Messersmith WA; LaBarbera DV
    Oncogene; 2016 Sep; 35(38):4990-9. PubMed ID: 26947016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
    Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
    Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIASy-dependent SUMOylation regulates DNA topoisomerase IIalpha activity.
    Ryu H; Furuta M; Kirkpatrick D; Gygi SP; Azuma Y
    J Cell Biol; 2010 Nov; 191(4):783-94. PubMed ID: 21079245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
    Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
    Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
    Kwon Y; Shin BS; Chung IK
    J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
    Islam MS; Park S; Song C; Kadi AA; Kwon Y; Rahman AF
    Eur J Med Chem; 2017 Jan; 125():49-67. PubMed ID: 27654394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
    Ozawa Y; Kusano K; Owa T; Yokoi A; Asada M; Yoshimatsu K
    Cancer Chemother Pharmacol; 2012 May; 69(5):1353-62. PubMed ID: 22349812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
    Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
    Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
    Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
    Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
    Shapiro AB; Austin CA
    Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.